Propanc Biopharma Statistics
Total Valuation
PPCB has a market cap or net worth of $1.44 million. The enterprise value is $1.48 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PPCB has 836,025 shares outstanding. The number of shares has increased by 1,265.50% in one year.
| Current Share Class | 836,025 |
| Shares Outstanding | 836,025 |
| Shares Change (YoY) | +1,265.50% |
| Shares Change (QoQ) | +67.87% |
| Owned by Insiders (%) | 28.50% |
| Owned by Institutions (%) | 4.64% |
| Float | 597,735 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.16 |
| P/TBV Ratio | 0.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.37, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.37 |
| Quick Ratio | 0.13 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -27.95 |
Financial Efficiency
Return on equity (ROE) is -126.98% and return on invested capital (ROIC) is -74.71%.
| Return on Equity (ROE) | -126.98% |
| Return on Assets (ROA) | -62.31% |
| Return on Invested Capital (ROIC) | -74.71% |
| Return on Capital Employed (ROCE) | -169.22% |
| Weighted Average Cost of Capital (WACC) | 43.12% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$9.65M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.22% in the last 52 weeks. The beta is 3.40, so PPCB's price volatility has been higher than the market average.
| Beta (5Y) | 3.40 |
| 52-Week Price Change | -97.22% |
| 50-Day Moving Average | 2.41 |
| 200-Day Moving Average | 21.19 |
| Relative Strength Index (RSI) | 37.26 |
| Average Volume (20 Days) | 63,434 |
Short Selling Information
The latest short interest is 617,010, so 73.80% of the outstanding shares have been sold short.
| Short Interest | 617,010 |
| Short Previous Month | 523,788 |
| Short % of Shares Out | 73.80% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.10 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -18.37M |
| Pretax Income | -18.36M |
| Net Income | -19.29M |
| EBITDA | -18.37M |
| EBIT | -18.37M |
| Earnings Per Share (EPS) | -$32.46 |
Full Income StatementBalance Sheet
The company has $443,702 in cash and $573,873 in debt, with a net cash position of -$130,171 or -$0.16 per share.
| Cash & Cash Equivalents | 443,702 |
| Total Debt | 573,873 |
| Net Cash | -130,171 |
| Net Cash Per Share | -$0.16 |
| Equity (Book Value) | 10.83M |
| Book Value Per Share | 11.24 |
| Working Capital | 4.75M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.13 million and capital expenditures -$4,912, giving a free cash flow of -$4.14 million.
| Operating Cash Flow | -4.13M |
| Capital Expenditures | -4,912 |
| Depreciation & Amortization | 744 |
| Net Borrowing | -518,660 |
| Free Cash Flow | -4.14M |
| FCF Per Share | -$4.95 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
